These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29467650)

  • 21. Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction.
    Lee JJ; Kong M
    Stat Biopharm Res; 2009 Feb; 1(1):4-17. PubMed ID: 20037663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug Combinations: Tests and Analysis with Isoboles.
    Tallarida RJ
    Curr Protoc Pharmacol; 2016 Mar; 72():9.19.1-9.19.19. PubMed ID: 26995550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding synergy.
    Geary N
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(3):E237-53. PubMed ID: 23211518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
    Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
    Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators.
    Repash EM; Pensabene KM; Palenchar PM; Eggler AL
    Front Pharmacol; 2021; 12():686201. PubMed ID: 34163365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
    Meletiadis J; Verweij PE; TeDorsthorst DT; Meis JF; Mouton JW
    Med Mycol; 2005 Mar; 43(2):133-52. PubMed ID: 15832557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
    Dressler V; Müller G; Sühnel J
    Comput Biomed Res; 1999 Apr; 32(2):145-60. PubMed ID: 10337496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical detection of synergy: New methods and a comparative study.
    Thas O; Tourny A; Verbist B; Hawinkel S; Nazarov M; Mutambanengwe K; Bijnens L
    Pharm Stat; 2022 Mar; 21(2):345-360. PubMed ID: 34608741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Methods for Quantifying Drug Synergism.
    Ma J; Motsinger-Reif A
    Proteom Bioinform; 2019 Jul; 1(2):43-48. PubMed ID: 32043089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-administration of morphine and gabapentin leads to dose dependent synergistic effects in a rat model of postoperative pain.
    Papathanasiou T; Juul RV; Heegaard AM; Kreilgaard M; Lund TM
    Eur J Pharm Sci; 2016 Jan; 82():97-105. PubMed ID: 26610393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies.
    Whitehead A; Su TL; Thygesen H; Sperrin M; Harbron C
    Pharm Stat; 2013; 12(5):300-8. PubMed ID: 23907796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling synergistic effects by using general Hill-type response surfaces describing drug interactions.
    Schindler M
    Sci Rep; 2022 Jun; 12(1):10524. PubMed ID: 35732854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the Effect of Mycotoxin Combinations: Which Mathematical Model Is (the Most) Appropriate?
    Kifer D; Jakšić D; Šegvić Klarić M
    Toxins (Basel); 2020 Feb; 12(3):. PubMed ID: 32121330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flexible interaction model for complex interactions of multiple anesthetics.
    Fidler M; Kern SE
    Anesthesiology; 2006 Aug; 105(2):286-96. PubMed ID: 16871062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
    Levasseur LM; Greco WR; Rustum YM; Slocum HK
    Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen.
    Perez DR; Edwards BS; Sklar LA; Chigaev A
    SLAS Discov; 2018 Aug; 23(7):751-760. PubMed ID: 29842834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
    Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG
    Mol Cancer Ther; 2014 Jul; 13(7):1964-76. PubMed ID: 24755197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A four-step approach to evaluate mixtures for consistency with dose addition.
    Hertzberg RC; Pan Y; Li R; Haber LT; Lyles RH; Herr DW; Moser VC; Simmons JE
    Toxicology; 2013 Nov; 313(2-3):134-44. PubMed ID: 23146763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing for additivity at select mixture groups of interest based on statistical equivalence testing methods.
    Stork LG; Gennings C; Carchman RA; Carter WH; Pounds J; Mumtaz M
    Risk Anal; 2006 Dec; 26(6):1601-12. PubMed ID: 17184400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.